urea has been researched along with Cognition Disorders in 17 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Approaches, such as vasopressin receptor antagonists or urea, have been shown to reverse moderate hyponatremia." | 4.89 | Hyponatremia: an update on current pharmacotherapy. ( Schrier, RW; Shchekochikhin, D; Tkachenko, O, 2013) |
| "PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms." | 2.87 | Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications. ( Andersson, C; Ballard, C; Coate, B; Espay, AJ; Factor, SA; Fredericks, D; Friedman, JH; Guskey, MT; Lang, AE; Larsen, NJ; Norton, JC; Vizcarra, JA; Weintraub, D, 2018) |
| "Neuropsychiatric symptoms are common in Alzheimer's disease (AD) and other neurodegenerative disorders." | 2.52 | Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. ( Cummings, J; Zhong, K, 2015) |
| " Further study is needed to determine whether these results concerning mechanism and dosage can be the basis for prevention of the development of CIS in at risk populations." | 1.38 | Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist. ( Adelekun, AE; Hannaway, KE; Horiguchi, M; Jayathilake, K; Meltzer, HY, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (17.65) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Espay, AJ | 1 |
| Guskey, MT | 1 |
| Norton, JC | 1 |
| Coate, B | 1 |
| Vizcarra, JA | 1 |
| Ballard, C | 1 |
| Factor, SA | 1 |
| Friedman, JH | 1 |
| Lang, AE | 1 |
| Larsen, NJ | 1 |
| Andersson, C | 1 |
| Fredericks, D | 1 |
| Weintraub, D | 1 |
| Geraghty, AC | 1 |
| Gibson, EM | 1 |
| Ghanem, RA | 1 |
| Greene, JJ | 1 |
| Ocampo, A | 1 |
| Goldstein, AK | 1 |
| Ni, L | 1 |
| Yang, T | 1 |
| Marton, RM | 1 |
| Paşca, SP | 1 |
| Greenberg, ME | 1 |
| Longo, FM | 1 |
| Monje, M | 1 |
| Shchekochikhin, D | 1 |
| Tkachenko, O | 1 |
| Schrier, RW | 1 |
| Gurkoff, GG | 1 |
| Feng, JF | 1 |
| Van, KC | 1 |
| Izadi, A | 1 |
| Ghiasvand, R | 1 |
| Shahlaie, K | 1 |
| Song, M | 1 |
| Lowe, DA | 1 |
| Zhou, J | 1 |
| Lyeth, BG | 1 |
| Cummings, J | 1 |
| Zhong, K | 1 |
| Enns, GM | 1 |
| Mehta, MA | 1 |
| Gore-Langton, E | 1 |
| Golembo, N | 1 |
| Colvert, E | 1 |
| Williams, SC | 1 |
| Sonuga-Barke, E | 1 |
| Labudda, K | 1 |
| Brand, M | 1 |
| Mertens, M | 1 |
| Ebner, A | 1 |
| Markowitsch, HJ | 1 |
| Woermann, FG | 1 |
| Marquis, KL | 1 |
| Comery, TA | 1 |
| Jow, F | 1 |
| Navarra, RL | 1 |
| Grauer, SM | 1 |
| Pulicicchio, C | 1 |
| Kelley, C | 1 |
| Brennan, JA | 1 |
| Roncarati, R | 1 |
| Scali, C | 1 |
| Haydar, S | 1 |
| Ghiron, C | 1 |
| Terstappen, GC | 1 |
| Dunlop, J | 1 |
| Horiguchi, M | 1 |
| Hannaway, KE | 1 |
| Adelekun, AE | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| King, MR | 1 |
| Anderson, NJ | 1 |
| Guernsey, LS | 1 |
| Jolivalt, CG | 1 |
| Gropman, AL | 1 |
| Batshaw, ML | 2 |
| Faghih, R | 1 |
| Gfesser, GA | 1 |
| Gopalakrishnan, M | 1 |
| O'Keeffe, ST | 1 |
| Lavan, JN | 1 |
| Msall, M | 1 |
| Monahan, PS | 1 |
| Chapanis, N | 1 |
| Schydlo, R | 1 |
| Cormier, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Adverse Effects of Subcutaneous vs Intravenous Hydration on Older Acutely Admitted Patients: An Assessor-blinded, Non-inferiority RCT[NCT03710408] | 51 participants (Actual) | Interventional | 2019-01-20 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for urea and Cognition Disorders
| Article | Year |
|---|---|
Hyponatremia: an update on current pharmacotherapy.
Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Brain Edema; Chronic Disease; Clinical Trials as To | 2013 |
Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
Topics: Alzheimer Disease; Apathy; Citalopram; Clinical Trials as Topic; Cognition Disorders; Humans; Mental | 2015 |
Neurologic damage and neurocognitive dysfunction in urea cycle disorders.
Topics: Brain Edema; Carbamoyl-Phosphate Synthase I Deficiency Disease; Cognition Disorders; Glutamine; Huma | 2008 |
Cognitive outcome in urea cycle disorders.
Topics: Age of Onset; Child; Cognition Disorders; Female; Humans; Hyperammonemia; Intellectual Disability; M | 2004 |
Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
Topics: Allosteric Regulation; alpha7 Nicotinic Acetylcholine Receptor; Animals; Bridged Bicyclo Compounds, | 2007 |
Cognitive development in children with inborn errors of urea synthesis.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Child; Child, Preschool; Cognition Disorder | 1988 |
2 trials available for urea and Cognition Disorders
| Article | Year |
|---|---|
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Cognition Disorders; Double-Blind Method; Female; Hum | 2018 |
Subcutaneous fluids in elderly hospital patients with cognitive impairment.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Confusion; Costs and Cost Analysis; Creatinine; Female | 1996 |
9 other studies available for urea and Cognition Disorders
| Article | Year |
|---|---|
Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cerebral Cortex; Channelrhodopsins; Cognition Disorders; | 2019 |
NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia.
Topics: Animals; Brain Injuries; Cognition Disorders; Disease Models, Animal; Glutamate Carboxypeptidase II; | 2013 |
Hyporesponsive reward anticipation in the basal ganglia following severe institutional deprivation early in life.
Topics: Adolescent; Analysis of Variance; Basal Ganglia; Carbamide Peroxide; Case-Control Studies; Cognition | 2010 |
Alterations of decision making and underlying neural correlates after resection of a mediofrontal cortical dysplasia: A single case study.
Topics: Attention; Brain Mapping; Carbamide Peroxide; Cognition Disorders; Decision Making; Executive Functi | 2010 |
Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Antipsychotic Agents; Avoidance Learning; Cognitio | 2011 |
Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist.
Topics: Animals; Cognition Disorders; Disease Models, Animal; Dopamine D2 Receptor Antagonists; Female; Halo | 2012 |
Glycogen synthase kinase-3 inhibition prevents learning deficits in diabetic mice.
Topics: Animals; Cerebral Cortex; Cognition Disorders; Diabetes Mellitus, Experimental; Female; Glycogen Syn | 2013 |
[Heavy intoxication as a side-effect of CARBROMAL in two children (author's transl)].
Topics: Ataxia; Basal Ganglia Diseases; Child, Preschool; Cognition Disorders; Gait; Humans; Infant; Male; M | 1974 |
[The acute ischemic syndrome. Physiopathology].
Topics: Acidosis; Acute Disease; Anuria; Blood Vessels; Cognition Disorders; Edema; Extremities; Humans; Hyp | 1974 |